BioSystems Highlights New iFOB Integral System at MedLab 2019
By LabMedica International staff writers Posted on 31 Jan 2019 |
Image: The new Fecal Occult blood integral system (Photo courtesy of BioSystems).
BioSystems S.A. (Barcelona, Spain) presented its analytical systems at MedLab Middle East 2019 held in Dubai, UAE, from February 4-7, 2019. MedLab Middle East 2019 attracted more than 19,610 unique visitors and the exhibition floor area housed 678+ exhibitors dedicated to sharing the most recent technology available in the IVD, and medical laboratory market. The MedLab Congress also enjoyed massive growth, welcoming more than 6,000 delegates to the multi-track conferences this year.
At MedLab Middle East 2019, BioSystems presented its new Fecal Occult Blood (iFOB) integral system, which provides a diagnostic solution for FOB testing. Colorectal cancer (CRC) is the third-most common cancer and the fourth-leading cause of cancer-related deaths in the world. CRC is treatable and preventable if it is detected in the early stages, with the detection of fecal occult blood being the key to preventing colorectal cancer.
BioSystems’ new iFOB system is comprised of an easy-to-use stool collection tube for easy sampling at the patient’s home or in the laboratory, an improved immunoturbidimetric assay in the form of a new and high sensitive antibody against human hemoglobin (no cross reaction with non-human Hb), an updated version of the company’s A15 analyzer with a new cap piercing function (no need to decap or recap samples tube after testing), and a dedicated software for fecal samples.
The iFOB system provides an accurate, reliable and safe method for FOB testing, making this test accessible to any kind of laboratory. In addition to FOB tests, BioSystems’ integral system can be updated with new fecal tests such as fecal Calprotectin, Transferrin and Helicobacter pylori, making the system a complete solution for stool samples analysis in the laboratory.
At MedLab Middle East 2019, BioSystems presented its new Fecal Occult Blood (iFOB) integral system, which provides a diagnostic solution for FOB testing. Colorectal cancer (CRC) is the third-most common cancer and the fourth-leading cause of cancer-related deaths in the world. CRC is treatable and preventable if it is detected in the early stages, with the detection of fecal occult blood being the key to preventing colorectal cancer.
BioSystems’ new iFOB system is comprised of an easy-to-use stool collection tube for easy sampling at the patient’s home or in the laboratory, an improved immunoturbidimetric assay in the form of a new and high sensitive antibody against human hemoglobin (no cross reaction with non-human Hb), an updated version of the company’s A15 analyzer with a new cap piercing function (no need to decap or recap samples tube after testing), and a dedicated software for fecal samples.
The iFOB system provides an accurate, reliable and safe method for FOB testing, making this test accessible to any kind of laboratory. In addition to FOB tests, BioSystems’ integral system can be updated with new fecal tests such as fecal Calprotectin, Transferrin and Helicobacter pylori, making the system a complete solution for stool samples analysis in the laboratory.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions